SOLS beats Q1, but UBS already stepped aside

Options positioning told the caution story ahead of the print. The put/call ratio peaked above 2.0 in mid-to-late April — more than double what it was in late March — before easing to 1.77 by May 5. That's still above its 20-day average of 1.73, but the direction of travel is toward unwinding rather than building fresh protection. The 52-week range on the PCR is 0.27 to 4.78; the current reading is elevated but nowhere near panic territory. Borrow conditions remain thoroughly relaxed: the cost to borrow is running below 0.50%, short interest at roughly 2% of the free float is down 5% from a month ago, and availability in the lending market is extremely loose relative to the small short base. Days to cover is under two. There is no short-seller pressure story here.

The Street's posture heading into earnings was notably cautious. UBS downgraded SOLS to Neutral in mid-April, maintaining a $87 price target — a level the stock has not yet reached but is now approaching at $83.56. That move — sidelining ahead of a clean print — will draw scrutiny. No other analyst changes appeared in recent data for this name. Valuation multiples have drifted up with the price: the P/E has risen roughly 5.3 points over 30 days to 29.5x, and EV/EBITDA has expanded about 0.3x over the same period to 14.6x. For a specialty chemicals company generating roughly $1 billion in EBITDA on $4 billion in annual revenues, neither is obviously cheap, but neither is stretched enough to be the overriding concern. The ORTEX short score of 29, unchanged for weeks, confirms short sellers are not positioning around a thesis.

The last earnings reaction offers the most useful reference point. At the Q4 2025 print in February, SOLS surged 22% on the day and extended to 27% over the following five sessions — the kind of move that explains why options traders spent the past month buying protection. That reaction came after a year in which net income dropped to $237 million from $594 million the prior year, while revenue still grew from $3.77 billion to $3.89 billion. The Q1 2026 beat, arriving as forward guidance was reaffirmed across the full year, suggests the profitability trajectory is recovering — a narrative that could matter more to holders than the modest beat in isolation.

Institutional ownership is broad and passive-heavy. Vanguard and BlackRock together hold around 20% of shares, and BlackRock added over 5.2 million shares in the most recent quarter. State Street and Goldman Sachs Asset Management also reported new positions as of March 31. Insider activity has been limited to routine award-and-sell patterns around vest dates, with the CFO selling a small parcel in February at $79.29 and a Senior VP selling a similar tranche last week at $81.58. Net insider value sold over 90 days totals roughly $668,000 — small in absolute terms, characteristic of standard compensation-driven sales rather than a directional signal.

The watch list item after today's print is straightforward: whether the UBS Neutral with an $87 target prompts a formal revision now that the clean guide has arrived, and whether the options market's steadily deflating put/call ratio continues toward the more neutral readings seen in March.